NO300138B1 - Anti-thrombinpolypeptider - Google Patents

Anti-thrombinpolypeptider Download PDF

Info

Publication number: NO300138B1
Authority: NO; Norway
Prior art keywords: polypeptide; sequence; dna sequence; thrombin; codes
Prior art date: 1991-02-28

Application number

NO920777A

Other languages

English (en)

Norwegian (no)

Other versions

NO920777D0 (no

NO920777L (no

Inventor

Paolo Sarmientos

Philippe De Taxis Du Poet

Giampaolo Nitti

Emanuela Scacheri

Original Assignee

Pharmacia & Upjohn Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-02-28

Filing date

1992-02-27

Publication date

1997-04-14

1991-02-28 Priority claimed from GB919104260A external-priority patent/GB9104260D0/en

1991-09-18 Priority claimed from GB919119954A external-priority patent/GB9119954D0/en

1992-02-27 Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa

1992-02-27 Publication of NO920777D0 publication Critical patent/NO920777D0/no

1992-08-31 Publication of NO920777L publication Critical patent/NO920777L/no

1997-04-14 Publication of NO300138B1 publication Critical patent/NO300138B1/no

Links

108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 123
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 121
229920001184 polypeptide Polymers 0.000 claims abstract description 116
238000000034 method Methods 0.000 claims abstract description 34
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 32
239000013604 expression vector Substances 0.000 claims abstract description 23
230000028327 secretion Effects 0.000 claims abstract description 20
210000004027 cell Anatomy 0.000 claims description 50
239000013612 plasmid Substances 0.000 claims description 32
150000003839 salts Chemical class 0.000 claims description 30
239000000203 mixture Substances 0.000 claims description 28
108010076504 Protein Sorting Signals Proteins 0.000 claims description 22
241000588724 Escherichia coli Species 0.000 claims description 20
241000238631 Hexapoda Species 0.000 claims description 19
241000701447 unidentified baculovirus Species 0.000 claims description 18
239000013598 vector Substances 0.000 claims description 16
101710182846 Polyhedrin Proteins 0.000 claims description 15
239000004480 active ingredient Substances 0.000 claims description 12
239000002299 complementary DNA Substances 0.000 claims description 12
238000004519 manufacturing process Methods 0.000 claims description 11
241000700605 Viruses Species 0.000 claims description 8
108020001507 fusion proteins Proteins 0.000 claims description 8
102000037865 fusion proteins Human genes 0.000 claims description 8
241000256251 Spodoptera frugiperda Species 0.000 claims description 7
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 5
241001465754 Metazoa Species 0.000 claims description 4
241000894006 Bacteria Species 0.000 claims description 3
210000004962 mammalian cell Anatomy 0.000 claims description 3
BOKLLPVAQDSLHC-FXQIFTODSA-N Ala-Val-Cys Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)O)N BOKLLPVAQDSLHC-FXQIFTODSA-N 0.000 claims description 2
JHCVYQKVKOLAIU-NAKRPEOUSA-N Ile-Cys-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)O)N JHCVYQKVKOLAIU-NAKRPEOUSA-N 0.000 claims description 2
BGZCJDGBBUUBHA-KKUMJFAQSA-N Leu-Lys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O BGZCJDGBBUUBHA-KKUMJFAQSA-N 0.000 claims description 2
JQHYVIKEFYETEW-IHRRRGAJSA-N Met-Phe-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=CC=C1 JQHYVIKEFYETEW-IHRRRGAJSA-N 0.000 claims description 2
XNLUVJPMPAZHCY-JYJNAYRXSA-N Val-Val-Phe Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 XNLUVJPMPAZHCY-JYJNAYRXSA-N 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
238000002474 experimental method Methods 0.000 claims description 2
108010030617 leucyl-phenylalanyl-valine Proteins 0.000 claims description 2
108010073101 phenylalanylleucine Proteins 0.000 claims description 2
241000276498 Pollachius virens Species 0.000 claims 5
125000003275 alpha amino acid group Chemical group 0.000 claims 4
240000004808 Saccharomyces cerevisiae Species 0.000 claims 2
241000212384 Bifora Species 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
230000023597 hemostasis Effects 0.000 claims 1
150000001413 amino acids Chemical class 0.000 abstract description 29
239000004019 antithrombin Substances 0.000 abstract description 28
108090000190 Thrombin Proteins 0.000 abstract description 22
229960004072 thrombin Drugs 0.000 abstract description 22
238000002360 preparation method Methods 0.000 abstract description 15
241000500851 Poecilobdella manillensis Species 0.000 abstract description 10
238000011282 treatment Methods 0.000 abstract description 4
108020004511 Recombinant DNA Proteins 0.000 abstract description 2
206010052664 Vascular shunt Diseases 0.000 abstract description 2
206010047249 Venous thrombosis Diseases 0.000 abstract description 2
208000009190 disseminated intravascular coagulation Diseases 0.000 abstract description 2
230000004481 post-translational protein modification Effects 0.000 abstract description 2
108090000623 proteins and genes Proteins 0.000 description 37
230000000694 effects Effects 0.000 description 21
235000018102 proteins Nutrition 0.000 description 19
102000004169 proteins and genes Human genes 0.000 description 19
108020004414 DNA Proteins 0.000 description 16
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
239000000872 buffer Substances 0.000 description 14
108091034117 Oligonucleotide Proteins 0.000 description 13
101150103068 P2 gene Proteins 0.000 description 13
238000010276 construction Methods 0.000 description 13
239000012634 fragment Substances 0.000 description 13
239000002773 nucleotide Substances 0.000 description 13
125000003729 nucleotide group Chemical group 0.000 description 13
239000000047 product Substances 0.000 description 13
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
235000001014 amino acid Nutrition 0.000 description 12
239000000243 solution Substances 0.000 description 12
239000000463 material Substances 0.000 description 11
238000012546 transfer Methods 0.000 description 11
241000711975 Vesicular stomatitis virus Species 0.000 description 10
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
108091006027 G proteins Proteins 0.000 description 8
102000030782 GTP binding Human genes 0.000 description 8
108091000058 GTP-Binding Proteins 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
230000001580 bacterial effect Effects 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
108091026890 Coding region Proteins 0.000 description 6
241000545744 Hirudinea Species 0.000 description 6
102000007625 Hirudins Human genes 0.000 description 6
108010007267 Hirudins Proteins 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
229920002684 Sepharose Polymers 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
239000008280 blood Substances 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
230000029087 digestion Effects 0.000 description 6
229940006607 hirudin Drugs 0.000 description 6
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 6
238000003752 polymerase chain reaction Methods 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
108020004705 Codon Proteins 0.000 description 5
101001121580 Enterobacteria phage PRD1 Adsorption protein P2 Proteins 0.000 description 5
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
108010079246 OMPA outer membrane proteins Proteins 0.000 description 5
101001125164 Parietaria judaica Probable non-specific lipid-transfer protein 2 Proteins 0.000 description 5
101000580771 Pseudomonas phage phi6 RNA-directed RNA polymerase Proteins 0.000 description 5
101001121571 Rice tungro bacilliform virus (isolate Philippines) Protein P2 Proteins 0.000 description 5
239000002253 acid Substances 0.000 description 5
230000003321 amplification Effects 0.000 description 5
238000003780 insertion Methods 0.000 description 5
230000037431 insertion Effects 0.000 description 5
238000003199 nucleic acid amplification method Methods 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
229960000723 ampicillin Drugs 0.000 description 4
239000002585 base Substances 0.000 description 4
230000003115 biocidal effect Effects 0.000 description 4
238000010367 cloning Methods 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
102000009123 Fibrin Human genes 0.000 description 3
108010073385 Fibrin Proteins 0.000 description 3
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
108700005078 Synthetic Genes Proteins 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000003146 anticoagulant agent Substances 0.000 description 3
229940127219 anticoagulant drug Drugs 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
238000003556 assay Methods 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000004087 circulation Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
239000003480 eluent Substances 0.000 description 3
229950003499 fibrin Drugs 0.000 description 3
239000000499 gel Substances 0.000 description 3
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
239000003921 oil Substances 0.000 description 3
239000002674 ointment Substances 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
239000008188 pellet Substances 0.000 description 3
210000001322 periplasm Anatomy 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
238000011321 prophylaxis Methods 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000004007 reversed phase HPLC Methods 0.000 description 3
239000001488 sodium phosphate Substances 0.000 description 3
229910000162 sodium phosphate Inorganic materials 0.000 description 3
235000011008 sodium phosphates Nutrition 0.000 description 3
239000012086 standard solution Substances 0.000 description 3
239000000758 substrate Substances 0.000 description 3
230000002194 synthesizing effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000014616 translation Effects 0.000 description 3
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
YDMBNDUHUNWWRP-VJBWXMMDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]piperidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C1=CC=CC=C1 YDMBNDUHUNWWRP-VJBWXMMDSA-N 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
239000005695 Ammonium acetate Substances 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000237902 Hirudo medicinalis Species 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
102100039087 Peptidyl-alpha-hydroxyglycine alpha-amidating lyase Human genes 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
108010039286 S 2238 Proteins 0.000 description 2
241000256248 Spodoptera Species 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
108010006785 Taq Polymerase Proteins 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
235000011054 acetic acid Nutrition 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
239000008272 agar Substances 0.000 description 2
238000007112 amidation reaction Methods 0.000 description 2
235000019257 ammonium acetate Nutrition 0.000 description 2
229940043376 ammonium acetate Drugs 0.000 description 2
150000003863 ammonium salts Chemical class 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000015271 coagulation Effects 0.000 description 2
238000005345 coagulation Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
238000010586 diagram Methods 0.000 description 2
238000010828 elution Methods 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
230000004927 fusion Effects 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
NUVBSKCKDOMJSU-UHFFFAOYSA-N para-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
238000012510 peptide mapping method Methods 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
230000007017 scission Effects 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000012064 sodium phosphate buffer Substances 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
239000006104 solid solution Substances 0.000 description 2
235000008522 spreadable oils and fats Nutrition 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000004448 titration Methods 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
239000003643 water by type Substances 0.000 description 2
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
LGKDEBYYRWXEDL-UHFFFAOYSA-N 2-aminobenzenecarboximidamide Chemical compound NC(=N)C1=CC=CC=C1N LGKDEBYYRWXEDL-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
WPANETAWYGDRLL-UHFFFAOYSA-N 4-aminobenzenecarboximidamide Chemical compound NC(=N)C1=CC=C(N)C=C1 WPANETAWYGDRLL-UHFFFAOYSA-N 0.000 description 1
KFDVPJUYSDEJTH-UHFFFAOYSA-N 4-ethenylpyridine Chemical compound C=CC1=CC=NC=C1 KFDVPJUYSDEJTH-UHFFFAOYSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
244000153158 Ammi visnaga Species 0.000 description 1
235000010585 Ammi visnaga Nutrition 0.000 description 1
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
241001367049 Autographa Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241001524679 Escherichia virus M13 Species 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
241000192125 Firmicutes Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
101710116435 Outer membrane protein Proteins 0.000 description 1
101710167677 Outer membrane protein P2 Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
101150062722 PDXP gene Proteins 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
102000013566 Plasminogen Human genes 0.000 description 1
108010051456 Plasminogen Proteins 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
101000993312 Poecilobdella manillensis Hirudin-HM2 Proteins 0.000 description 1
206010050902 Postoperative thrombosis Diseases 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000012505 Superdex™ Substances 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
208000001435 Thromboembolism Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
238000003811 acetone extraction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000011149 active material Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
-1 alkali metal salt Chemical class 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
230000009435 amidation Effects 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
235000012538 ammonium bicarbonate Nutrition 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002429 anti-coagulating effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
229960000182 blood factors Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
150000001734 carboxylic acid salts Chemical class 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
229960004106 citric acid Drugs 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000006743 cytoplasmic accumulation Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
239000003925 fat Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
235000003869 genetically modified organism Nutrition 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
229960004198 guanidine Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
229940106780 human fibrinogen Drugs 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229960000448 lactic acid Drugs 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
229940099690 malic acid Drugs 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
125000001477 organic nitrogen group Chemical group 0.000 description 1
229940098695 palmitic acid Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
108010007262 peptidylglycine monooxygenase Proteins 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
238000004321 preservation Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
201000005484 prostate carcinoma in situ Diseases 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
239000013014 purified material Substances 0.000 description 1
229940005657 pyrophosphoric acid Drugs 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
238000002390 rotary evaporation Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
238000002633 shock therapy Methods 0.000 description 1
239000002356 single layer Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000001587 sorbitan monostearate Substances 0.000 description 1
235000011076 sorbitan monostearate Nutrition 0.000 description 1
229940035048 sorbitan monostearate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
229960004274 stearic acid Drugs 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
230000008961 swelling Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229960001367 tartaric acid Drugs 0.000 description 1
230000009424 thromboembolic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
108010087967 type I signal peptidase Proteins 0.000 description 1
241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
108700001624 vesicular stomatitis virus G Proteins 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000004271 weak anion exchange chromatography Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Physics & Mathematics (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Plant Pathology (AREA)
Diabetes (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

NO920777A 1991-02-28 1992-02-27 Anti-thrombinpolypeptider NO300138B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB919104260A GB9104260D0 (en)	1991-02-28	1991-02-28	Anti-thrombin polypeptides
GB919119954A GB9119954D0 (en)	1991-09-18	1991-09-18	Antithrombin polypeptides

Publications (3)

Publication Number	Publication Date
NO920777D0 NO920777D0 (no)	1992-02-27
NO920777L NO920777L (no)	1992-08-31
NO300138B1 true NO300138B1 (no)	1997-04-14

Family

ID=26298509

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO920777A NO300138B1 (no)	1991-02-28	1992-02-27	Anti-thrombinpolypeptider

Country Status (23)

Country	Link
US (2)	US5356875A (hu)
EP (1)	EP0501821B1 (hu)
JP (1)	JPH05247090A (hu)
KR (1)	KR100218818B1 (hu)
CN (1)	CN1044479C (hu)
AT (1)	ATE175236T1 (hu)
AU (1)	AU643876B2 (hu)
CA (1)	CA2061920A1 (hu)
CZ (1)	CZ283458B6 (hu)
DE (1)	DE69228015T2 (hu)
DK (1)	DK0501821T3 (hu)
ES (1)	ES2129426T3 (hu)
FI (1)	FI920861A (hu)
GR (1)	GR3029364T3 (hu)
HU (1)	HU215580B (hu)
IE (1)	IE920622A1 (hu)
IL (1)	IL101062A0 (hu)
MX (1)	MX9200795A (hu)
MY (1)	MY110327A (hu)
NO (1)	NO300138B1 (hu)
NZ (1)	NZ241715A (hu)
TW (1)	TW214556B (hu)
YU (1)	YU19792A (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1266561B1 (it) *	1993-07-22	1997-01-09	Mini Ricerca Scient Tecnolog	Analoghi di un polipeptide anti-trombinico e procedimento per la loro preparazione
CN1064968C (zh) *	1996-07-10	2001-04-25	中国人民解放军第一军医大学	重组蛋白提取纯化方法
KR20000070338A (ko)	1997-01-20	2000-11-25	나가시마 카쭈시게, 노미야마 아키히코	펩티드의 안정화 방법 및 당해 방법을 이용한 펩티드 함유 동결건조 의약조성물
US6077825A (en)	1997-03-13	2000-06-20	Auburn University	Antithrombin protein and DNA sequences from black fly
JP2000080046A (ja) *	1998-09-03	2000-03-21	Dai Ichi Seiyaku Co Ltd	多臓器障害の予防・治療剤
CN102876654A (zh) *	2012-10-19	2013-01-16	广东海洋大学	一种桑蚕丝素固定化凝血酶的制备方法
CN104193809B (zh) *	2014-09-28	2016-08-17	顾玉奎	一种凝血酶抑制及其制备方法、应用
CN104193807B (zh) *	2014-09-28	2016-06-15	广州贝奥吉因生物科技有限公司	凝血酶抑制多肽及其制备方法、应用
CN105646702B (zh) *	2016-04-13	2019-03-01	中国科学院昆明动物研究所	菲牛蛭Kazal型胰蛋白酶抑制剂Bdellin-HM及其编码基因和应用
CN108059672B (zh) *	2016-11-08	2021-06-11	中国科学院昆明动物研究所	森林山蛭抗血栓肽Sylvestin及其基因和应用
CN110468174A (zh) *	2019-08-21	2019-11-19	北京中医药大学	一种水蛭活性寡肽的制备方法
CN111454352B (zh) *	2020-03-05	2021-07-23	中国科学院昆明动物研究所	一种活性蛋白hmei-a、活性蛋白hmei-a的编码基因及应用
CN112114069B (zh) *	2020-09-18	2023-05-16	江苏艾迪药业股份有限公司	凝血酶的亲和色谱柱、制备方法及应用
CN112480210B (zh) *	2020-11-25	2021-09-17	广东海洋大学	一种抗凝血活性肽及其用途
KR102354461B1 (ko) *	2021-02-19	2022-01-20	김건언	덕트 일체형 조명등기구
CN115572329B (zh) *	2021-06-21	2024-02-06	王大勇	一组活性增强代谢较慢的菲牛蛭基因重组水蛭素及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2052062T3 (es) *	1988-06-11	1994-07-01	Ciba Geigy Ag	Nuevos polipeptidos con actividad anticoagulante.
US5268296A (en) *	1988-06-11	1993-12-07	Ciba-Geigy Corporation	DNA vector and recombinant host cell for production of hirullin P6 and P18
GB8826428D0 (en) *	1988-11-11	1988-12-14	Biopharm Ltd	Antithrombin
IT1250689B (it) *	1991-07-22	1995-04-21	Marco Gerna	Analoghi dell'irudina e procedimento per la loro preparazione

1992
- 1992-02-24 IL IL101062A patent/IL101062A0/xx unknown
- 1992-02-25 AU AU11221/92A patent/AU643876B2/en not_active Ceased
- 1992-02-25 TW TW081101387A patent/TW214556B/zh active
- 1992-02-25 MX MX9200795A patent/MX9200795A/es not_active IP Right Cessation
- 1992-02-25 NZ NZ241715A patent/NZ241715A/en unknown
- 1992-02-25 HU HU9200620A patent/HU215580B/hu not_active IP Right Cessation
- 1992-02-26 KR KR1019920002964A patent/KR100218818B1/ko not_active IP Right Cessation
- 1992-02-26 US US07/842,089 patent/US5356875A/en not_active Expired - Fee Related
- 1992-02-26 CA CA002061920A patent/CA2061920A1/en not_active Abandoned
- 1992-02-26 FI FI920861A patent/FI920861A/fi unknown
- 1992-02-26 YU YU19792A patent/YU19792A/sh unknown
- 1992-02-27 NO NO920777A patent/NO300138B1/no unknown
- 1992-02-27 JP JP4075594A patent/JPH05247090A/ja active Pending
- 1992-02-27 CZ CS92584A patent/CZ283458B6/cs not_active IP Right Cessation
- 1992-02-27 CN CN92101143A patent/CN1044479C/zh not_active Expired - Fee Related
- 1992-02-27 IE IE062292A patent/IE920622A1/en not_active Application Discontinuation
- 1992-02-27 MY MYPI92000321A patent/MY110327A/en unknown
- 1992-02-28 AT AT92301721T patent/ATE175236T1/de not_active IP Right Cessation
- 1992-02-28 DK DK92301721T patent/DK0501821T3/da active
- 1992-02-28 DE DE69228015T patent/DE69228015T2/de not_active Expired - Fee Related
- 1992-02-28 EP EP92301721A patent/EP0501821B1/en not_active Expired - Lifetime
- 1992-02-28 ES ES92301721T patent/ES2129426T3/es not_active Expired - Lifetime
1994
- 1994-06-23 US US08/264,485 patent/US5439820A/en not_active Expired - Fee Related
1999
- 1999-02-10 GR GR990400451T patent/GR3029364T3/el unknown

Also Published As

Publication number	Publication date
FI920861A (fi)	1992-08-29
KR920016468A (ko)	1992-09-24
EP0501821A3 (en)	1993-03-03
HU9200620D0 (en)	1992-05-28
NZ241715A (en)	1993-07-27
NO920777D0 (no)	1992-02-27
DE69228015T2 (de)	1999-06-02
DK0501821T3 (da)	1999-08-30
JPH05247090A (ja)	1993-09-24
KR100218818B1 (ko)	1999-10-01
CN1044479C (zh)	1999-08-04
US5439820A (en)	1995-08-08
EP0501821B1 (en)	1998-12-30
HU215580B (hu)	1999-01-28
TW214556B (hu)	1993-10-11
AU643876B2 (en)	1993-11-25
IE920622A1 (en)	1992-09-09
MX9200795A (es)	1992-08-01
MY110327A (en)	1998-04-30
US5356875A (en)	1994-10-18
ES2129426T3 (es)	1999-06-16
GR3029364T3 (en)	1999-05-28
AU1122192A (en)	1992-09-03
DE69228015D1 (de)	1999-02-11
FI920861A0 (fi)	1992-02-26
EP0501821A2 (en)	1992-09-02
ATE175236T1 (de)	1999-01-15
YU19792A (sh)	1994-06-10
NO920777L (no)	1992-08-31
IL101062A0 (en)	1992-11-15
CN1066272A (zh)	1992-11-18
CZ283458B6 (cs)	1998-04-15
HUT64592A (en)	1994-01-28
CS58492A3 (en)	1992-09-16
CA2061920A1 (en)	1992-08-29

Publication	Publication Date	Title
NO300138B1 (no)	1997-04-14	Anti-thrombinpolypeptider
US5589359A (en)	1996-12-31	Chimeric proteins
Scacheri et al.	1993	Novel hirudin variants from the leech Hirudinaria manillensis: amino acid sequence, cDNA cloning and genomic organization
DK176140B1 (da)	2006-09-25	Flagermusspyt-plasminogenaktivatorer
EP0775711A1 (en)	1997-05-28	Peptide having antithrombotic activity and process for producing the same
JPH07503849A (ja)	1995-04-27	プロテアーゼ−耐性トロンボモジュリン・アナログ
CA2063575A1 (en)	1991-11-11	Method for the recombinant production of hirudins and hirudin-like polypeptides
Benatti et al.	1991	Secretion of biologically active leech hirudin from baculovirus-infected insect cells
EP0710285B1 (en)	2001-04-11	Analogues of an anti-thrombin polypeptide and process for their preparation
RU2131462C1 (ru)	1999-06-10	Фрагмент днк, рекомбинантный полипептид с антитромбиновой активностью, способ его получения (варианты), фармацевтическая композиция, рекомбинантный вектор (варианты)
NZ271088A (en)	1996-10-28	Desulphatohirudin muteins, their production, conjugates thereof and pharmaceutical compositions
NZ265507A (en)	1998-09-24	Peptide from hirudo medicinalis with anticoagulant activity, dna, plasmids and host plasmid systems
IE920768A1 (en)	1992-09-23	Proteins and nucleic acids
CN101838330A (zh)	2010-09-22	一种杀菌/通透性增强蛋白-人酸性成纤维细胞生长因子融合蛋白及其制备方法和应用
DK166730B (da)	1993-07-05	Humaninsulinanaloger og deres farmaceutisk tolerable salte samt farmaceutiske praeparater indeholdende disse